Natera v. Inivata: Voluntary Dismissal After 1,036 Days in Delaware
Natera, Inc. asserted US11530454B2 — a patent covering detection of mutations and ploidy in chromosomal segments — against liquid biopsy rival Inivata in the District of Delaware. After nearly three years of litigation, Natera voluntarily dismissed the consolidated case without prejudice, leaving the door open for future enforcement action.
A liquid biopsy patent clash that ended quietly — but not finally
On 20 December 2022, Natera, Inc. filed an infringement action in the District of Delaware against Inivata, Inc. and its UK parent Inivata, Ltd., asserting US11530454B2. The patent covers methods for detecting mutations and ploidy in chromosomal segments — core analytical steps in circulating cell-free DNA (cfDNA) cancer diagnostics. Both parties operate in the high-growth liquid biopsy market, making the dispute a direct competitive confrontation over foundational genomic sequencing methodology.
The case was terminated on 21 October 2025, when Natera filed a notice of voluntary dismissal without prejudice of the consolidated case. Voluntary dismissal without prejudice under Federal Rule of Civil Procedure 41(a) means no judgment was entered on the merits; crucially, it preserves Natera’s right to re-file claims based on the same patent against the same defendants at a future date, subject to applicable statutes of limitations and any court-imposed conditions.
The 1,036-day duration before dismissal suggests the litigation progressed well beyond initial pleadings — potentially through claim construction or discovery — before the parties reached a resolution or Natera elected to withdraw. The absence of a public settlement agreement or consent judgment means the commercial terms, if any, remain undisclosed. Whether Natera secured a licensing arrangement, a product design change by Inivata, or simply chose to discontinue cannot be confirmed from the public record.
Filing to Voluntary dismissal in 1036 days
1,036 days — nearly 3 years, longer than the median Delaware patent case
Voluntarily dismissed: what the notice means for both parties
Voluntary dismissal without prejudice — no merits ruling
A voluntary dismissal without prejudice under FRCP 41(a) terminates the action without any adjudication on the merits. No finding of infringement, validity, or invalidity was made. The public record contains a notice of voluntary dismissal of the consolidated case — the filing party (Natera) initiated the exit. This is categorically different from a defendant win or a court-ordered dismissal.
No judgment on meritsWithout prejudice vs. with prejudice — the public record is silent on which
The verdict text states ‘without prejudice’, meaning Natera retains the right to re-assert US11530454B2 against Inivata in a future action. Had the dismissal been ‘with prejudice’, Natera would be barred from re-litigating the same claims. The public docket does not disclose any settlement agreement, licensing terms, or covenant not to sue — so the underlying commercial resolution, if any, is unknown.
Re-filing remains possibleNatera preserves enforcement optionality on US11530454B2
Natera exits this action without a judgment that could be used against it. The patent remains in force and unchallenged by any court ruling in this case. If a licensing deal or design-around agreement was reached privately, Natera may have achieved its commercial objective without litigation risk. The strategic flexibility afforded by a without-prejudice exit is significant for a patent holder operating in a fast-moving diagnostics market.
Patent enforcement intactInivata avoids an adverse judgment — but faces residual risk
Inivata obtains no declaratory judgment of non-infringement or invalidity, which would have provided lasting legal protection. The without-prejudice nature of the dismissal means the infringement threat is not extinguished. Any competitor or acquirer conducting due diligence on Inivata should note that US11530454B2 remains a live risk unless a formal license, covenant, or invalidation is confirmed.
No declaratory relief obtainedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Natera, Inc. | Company | Genomic diagnostics company — holder of US11530454B2 (cfDNA mutation/ploidy detection)Search in Eureka ↗ |
| Defendant | Inivata, Inc. | Company | Liquid biopsy diagnostics firm (Inivata, Inc. and UK parent Inivata, Ltd.)Search in Eureka ↗ |
| Co-Defendant | Inivata, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Anthony David Raucci | Attorney | Counsel for Natera, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Derek James Fahnestock | Attorney | Counsel for Natera, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Natera, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Natera, Inc.Search in Eureka ↗ |
| Defendant counsel | Brian E. Farnan | Attorney | Counsel for Inivata, Inc.Search in Eureka ↗ |
| Defendant law firm | Farnan LLP | Law Firm | Representing Inivata, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The notice of voluntary dismissal without prejudice of the consolidated case is a procedural exit, not a substantive ruling. It carries no preclusive effect on the patent’s validity or on Inivata’s infringement exposure. The consolidation reference suggests Natera may have filed related actions that were joined — the dismissal appears to resolve all such consolidated claims simultaneously. Because no merits adjudication occurred, neither party can point to this case as precedent for or against the patent’s enforceability.
US11530454B2 — Detecting mutations and ploidy in chromosomal segments
US11530454B2, filed under application number US17/738354, protects methods for detecting mutations and ploidy in chromosomal segments — a foundational analytical layer in cfDNA-based oncology diagnostics. The patent covers the computational and biochemical methodology used to identify somatic mutations and copy number alterations from circulating tumour DNA, which is central to non-invasive cancer monitoring and minimal residual disease (MRD) detection. Its issuance as a utility patent reflects the depth of technical differentiation Natera has built into its Signatera platform.
In a liquid biopsy market projected to exceed $5 billion by the late 2020s, patents covering cfDNA analytical methods represent critical competitive moats. US11530454B2 sits at the intersection of sequencing methodology and bioinformatics — two areas where Natera has invested heavily in IP protection. Any company developing or commercialising cfDNA assays for oncology, prenatal testing, or transplant monitoring that involves chromosomal segment analysis should assess whether their workflow overlaps with the claims of this patent. The fact that Natera chose to assert it against a direct commercial rival underscores its perceived commercial significance.
Should your cfDNA assay be cleared against US11530454B2?
Any R&D team or product manager working on liquid biopsy assays that detect somatic mutations, copy number variation, or ploidy changes in cell-free DNA should treat US11530454B2 as a priority FTO target. This is particularly relevant for oncology monitoring platforms, MRD assays, and chromosomal instability panels. The patent’s enforcement history — including a three-year litigation against a commercial competitor — signals that Natera actively monitors the competitive landscape and is prepared to litigate.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US11530454B2 against your specific assay design, flagging independent claims most likely to read on cfDNA mutation detection workflows. Eureka also surfaces related Natera family members, prosecution history, and citation networks — giving your IP team a complete picture of the cfDNA patent thicket before product launch or investment decision.
Run a freedom-to-operate analysis on US11530454B2 to assess your product’s exposure
Run FTO in Eureka →Similar cfDNA and liquid biopsy patent cases in Delaware District Court
Explore related patent infringement cases involving cfDNA diagnostics and genomic sequencing asserted in the District of Delaware.
What this case signals for the cfDNA liquid biopsy IP landscape
A three-year Delaware dispute ending quietly without prejudice is a pattern worth tracking in competitive genomic diagnostics.
Without-prejudice exits can mask private licensing activity
When a plaintiff with a commercially valuable patent voluntarily dismisses after nearly three years — well into discovery or claim construction — it often suggests a private resolution rather than simple abandonment. Competitors and investors monitoring Natera’s enforcement strategy should treat this dismissal as a possible indicator of a confidential licensing or cross-licensing arrangement with Inivata.
US11530454B2 remains fully enforceable post-dismissal
No invalidity ruling, no claim construction adverse to Natera, and no IPR petition outcome is reflected in this case record. Any company working in cfDNA mutation detection or chromosomal ploidy analysis should treat this patent as an active enforcement risk. The absence of a judgment does not diminish its legal standing.
Natera v Inivata — key questions answered
The case was voluntarily dismissed without prejudice by Natera on 21 October 2025, after 1,036 days of litigation. No judgment was entered on the merits. The dismissal preserves Natera’s right to re-assert US11530454B2 against Inivata in a future action.
A voluntary dismissal without prejudice means no court ruled on whether US11530454B2 was infringed, valid, or invalid. The patent remains in full force. Natera retains the right to sue Inivata again on the same patent. Inivata obtained no declaratory judgment of non-infringement or invalidity.
US11530454B2 covers methods for detecting mutations and ploidy in chromosomal segments using cell-free DNA — a core methodology in liquid biopsy oncology diagnostics. Natera asserted it against Inivata, a direct competitor in the cfDNA diagnostics market, suggesting overlap between Inivata’s commercial assay products and the patent’s claims.
Delaware is a preferred venue for sophisticated patent plaintiffs due to its experienced judiciary, established local patent rules, and familiarity with complex technical litigation. Both Inivata entities were subject to Delaware jurisdiction, consistent with standard practice for companies incorporated or registered there. Judge Gregory B. Williams presided over the case.
The public record does not disclose a settlement or covenant not to sue, which means US11530454B2 remains an unresolved risk factor for any entity that assumed Inivata’s business and product lines. Acquirers and investors in NeoGenomics should assess whether the Inivata cfDNA product portfolio has been cleared against Natera’s patent estate, as no court ruling provides protection in this case.
PatSnap Eureka searches patents and litigation data to answer instantly.